Novartis’ Chinook Therapeutics-Originated Kidney Disease Drug Gets Accelerated Approval

Vanrafia, originally developed by Chinook Therapeutics and acquired by Novartis, has received accelerated FDA approval for treating IgA nephropathy (IgAN) in patients at risk of rapid progression. The once-daily pill, used alongside standard care, showed a 36.1% reduction in proteinuria in the ALIGN trial.